ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0204

Persistence of Fatigue, Sleep Disturbance and Mood Disorders in PMR Patients Despite Standard Treatment

Jessica Leung1, Claire Owen2, David Liew3 and Russell Buchanan3, 1Austin Health, Preston, Victoria, Australia, 2Austin Health, Malvern East, Australia, 3Austin Health, Heidelberg, Australia

Meeting: ACR Convergence 2022

Keywords: Anxiety, depression, Fatigue, Polymyalgia Rheumatica (PMR), sleep

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Patient Outcomes, Preferences, and Attitudes Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Polymyalgia rheumatica (PMR) is typified by pain and stiffness of the shoulder and hip girdles. Previous qualitative studies have highlighted the importance to patients of additional symptoms including fatigue and sleep disturbance. These features of PMR are less recognised by clinicians and have not yet been quantified in the literature. Furthermore, the adequacy of the current treatment paradigm in addressing these symptoms is unknown.

Methods: Patients with a new diagnosis of PMR fulfilling 2012 EULAR/ACR Provisional Classification Criteria were prospectively recruited, together with age- and gender-matched controls. Assessments were undertaken three months after the commencement of corticosteroid therapy, when it was considered likely that inflammatory disease would be controlled.

PMR disease activity was assessed using the PMR-Activity Score (PMR-AS). Patient-reported outcomes were used to assess fatigue (BRAF-MDQ), sleep (PSQI), anxiety and depression (HADS). The two-sample t-test and Mann-Whitney U test were conducted to compare scores in PMR participants versus control participants.

Results: Over the period April 2019 to August 2021, 36 participants with PMR and 32 control participants were recruited. The mean age of PMR participants was 68.7 (SD 8.3) years and 18 (50%) were females. The mean duration of steroid therapy prior to study assessments was 12.8 (SD 2.1) weeks. Disease activity at the time of assessments was low (median PMR-AS 4.1; IQR 1.7, 10.2).

PMR participants had a higher PSQI score compared to control participants, indicating lower quality sleep (mean 8.8 [SD 4.5] vs 5.3 [SD 2.9], difference 3.6 [95% CI 1.8 – 5.4], p< 0.001). The median BRAF score in PMR participants was higher than in control participants (22 [IQR 2, 32.5] vs 6 [IQR 2, 14.5], p=0.004). Median HAD depression and HAD anxiety scores were also higher in PMR participants (3 [IQR 2, 7] vs 1 [IQR 0, 3], p< 0.001; and 5 [IQR 3, 8] vs 2 [IQR 0, 3.5], p< 0.001 respectively).

Conclusion: Despite treatment-induced low disease activity at the time of assessment, PMR participants had significantly higher levels of fatigue, anxiety, depression and poorer quality of sleep compared to control participants. These results support previous insights from qualitative studies and underscore shortfalls of the current treatment approach based on corticosteroid monotherapy. Future research should explore risk factors and both pharmacological and non-pharmacological management strategies.


Disclosures: J. Leung, Novartis, Fresenius Kabi, Eli Lilly, AbbVie; C. Owen, None; D. Liew, None; R. Buchanan, None.

To cite this abstract in AMA style:

Leung J, Owen C, Liew D, Buchanan R. Persistence of Fatigue, Sleep Disturbance and Mood Disorders in PMR Patients Despite Standard Treatment [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/persistence-of-fatigue-sleep-disturbance-and-mood-disorders-in-pmr-patients-despite-standard-treatment/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/persistence-of-fatigue-sleep-disturbance-and-mood-disorders-in-pmr-patients-despite-standard-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology